Cytokinetics Files Complaint on Patent Issue Against Bristol-Myers Squibb
By Grace Yoon
Cytokinetics filed a complaint against Bristol-Myers Squibb, and its subsidiary MyoKardia, seeking a declaratory judgment that its heart disease therapy does not infringe on an existing patent.
The complaint is seeking to preliminarily and permanently block the defendants from threatening or initiating infringement litigation against Cytokinetics, the company said in a filing with the Securities and Exchange Commission on Thursday.
Cytokinetics is seeking protection against possible claims it infringed on what it refers to as the '697 patent, in connection with its heart disease therapy MYQORZO. The complain was filed in federal district court in Delaware.
As part of its filing the company is also seeking a judgment to block claims against customers, dealers, suppliers, sellers or distributors of MYQORZO, or charging any of them with patent infringement.
Bristol-Myers Squibb did not immediately respond to a request for comment.
Write to Grace Yoon at grace.yoon@wsj.com
(END) Dow Jones Newswires
August 13, 2026 12:06 ET (16:06 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States